The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 697-704 , October 2008

Polycystic Ovarian Syndrome: An Evidence-Based Approach to Reducing Metabolic Consequences

  • Laura A. Ruby

      Affiliations

    • Laura A. Ruby, MS, CRNP, ACNP, is an endocrinology nurse practitioner at Wellspan Endocrinology in Gettysburg, PA. She has a special interest in managing women with PCOS and other pre-diabetic conditions.

References 

  1. Chang R . The reproductive phenotype in polycytic ovary syndrome . Nat Clin Pract Endocrinol Metab . 2007;3(10):688–695
  2. Dunitz M . Polycystic ovarian syndrome . Boston: Blackwell Science, Inc.; 2001;
  3. Dhindsa G , Bhatia R , Bhatia V . Insulin resistance, insulin sensitization and inflammation in polycystic ovarian syndrome . J Postgrad Med . 2004;50(2):140–144
  4. Zawadski JK , Dunaif A . Diagnostic criteria for polycystic ovarian syndrome: towards a rational approach . In:  Dunaif A ,  Givens JR ,  Haseltine FP ,  Merriam GE editor. Polycystic ovary syndrome . 1192: Boston: Blackwell Scientific Publications; 2001;p. 337
  5. Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group  . Revised 2003 consensus on diagnostic criteria & long term health risks related to polycystic ovarian syndrome . Hum Reprod . 2004;19:41–47
  6. Barbieri R , Ehrmann D . Clinical manifestations of polycystic ovarian syndrome. UpToDate [serial online]. 2007;Version 16.1:5/8/08 . Available from: http://www.uptodate.com/ Accessed May 18, 2008.
  7. Carmina E . Diagnosing PCOS in women who menstruate regularly . Contemporary Obstet Gynecol . 2003;48:53–64
  8. Ehrman DA . Polycystic ovary syndrome . New Engl J Med . 2005;352:1223
  9. Ehrman DA , Barnes R , Rosenfiled R , Cavaghan M . The prevalence of impaired glucose tolerance and diabetes in women with polycystic ovarian syndrome . Diabetes Care . 1999;22:141
  10. Bhatia V . Insulin resistance in polycystic ovarian disease . South Med J . 2005;98(9):902–909
  11. Pasquali R , Gambineri A . Insulin-sensitizing agents in polycytic ovary syndrome . Eur J Endocrinol . 2006;154:1360–1365
  12. American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee  . American association of clinical endocrinologists position statement on metabolic and cardiovascular consequences of polycystic ovary syndrome . Endocr Pract . 2005;11:126–134
  13. Hopkinson Z , Sattar N , Fleming R , Greer I . Polycystic ovarian syndrome: the metabolic syndrome comes to gynecology . BMJ . 1998;1–13
  14. Boulman N , Levy Y , Leiba R . Increased C-reactive protein levels in the polycystiv ovarian syndrome: marker of cardiovascular disease . J Clin Endocrinol Metabol . 2004;89:2160
  15. Pierpoint T , McKeigue PM , Isaacs AJ , et al.   Mortality of women with polycystic ovarian syndrome at long-term follow up . J Clin Epidemiol . 1998;51:581
  16. Wild S , Pierpoint T , McKeigue P , Jacobs H . Cardiovascular disease in women with polycystic ovary syndrome at long-term follow up: a retrospective cohort study . Clin Endocrinol . 2000;52:595
  17. Solomon CG , Hu FB , Dunaif A , et al.   Menstrual cycle irregularity and risk for future cardiovascular disease . J Clin Endocrinol Metab . 2002;87:2013
  18. Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group  . Revised 2003 consensus on diagnostic criteria and long-term health risk related to polycystic ovary syndrome (PCOS) . Hum Reprod . 2004;19:41
  19. American Diabetes Association  . Clinical practice recommendations 2005 . Diabetes Care . 2005;28(Suppl 1):S1–S79
  20. Laitinen J , Toponen S , Martikainen H , et al.   Body size from birth to adulthood as a predictor of self reported polycystic ovarian syndrome symptoms . Int J Obes Rel Metabol Disord . 2003;27:710–715
  21. Douglass C , Gower B , Darnell B , Ovalle F , Oster R , et al.   Role of diet in the treatment of polycystic ovary syndrome . Fertil Steril . 2006;85(3):679–688
  22. Moren L , Brinkworth G , Noakes M , Norman R . Symposium: diet, nutrition and exercise in reproduction. Effects of lifestyle modification in polycystic ovarian syndrome . Reprod BioMed . 2006;12(5):569–578
  23. Pasquali R , Antenucci D , Casimirri F , et al.   Clinical and hormonal characteristics of obese and amenorrheic women before and after weight loss . J Clin Endocrinol Metab . 1989;68:173
  24. Golderg R , Haffner S , Ratner R , Marcovina S , Fowler S . The effect of metformin & intensive lifestyle on the metabolic syndrome: the diabetes prevention program randomized trial . Annal Intern Med . 2005;142:611
  25. Hirschberg A , Naessen S , Stridberg M , et al.   Impaired cholecystokinin secretion and disturbed appetite regulation in women with PCOS . Gynecol Endocrinol . 2004;19:79–87
  26. Pasquali R , Gambineri A , Biscotti D , Vicennati V , Gagliardi L , et al.   Effect of long-term treament with metformin added to hypocaloric diet on body compostion, fat distribution, and androgen and insulin levels in abdominally obese women with and without the polycystic ovary syndrome . J Clin Endocrinol Metab . 2006;85(8):2767–2774
  27. Lam P , Cheung L , Haines C . Revisit of metformin treatment in polycystic ovarian syndrome . Gynecol Endocrinol . 2004;19:121–128
  28. Lord J , Flight I , Norman R . Insulin sensitizing drugs for polycystic ovarian syndrome . Cochrane Database Syst Rev . 2004;3:1–117
  29. Moghetti P , Castello R , Negir C , et al.   Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6 month trial followed by open, long-term clinical evaluation . J Clin Endocrinol Metab . 2000;85:139
  30. Santana L , Silvar M , Ferriani M , de Moura M , Foss M , et al.   Effect of metformin on the clinical and metabolic assessment of women with polycystic ovary syndrome . Gynecol Endocrinol . 2004;19:88–96
  31. Fleming R , Hopkinson Z , Wallace AM , et al.   Ovarian function and metabolic factors in women with oligomenorrhea treated with metformin in a randomized double blind placebo-controlled trial . J Clin Endocrinol Metab . 2002;87:569
  32. Kelly CJ , Gordon D . The effect of metformin on hirsutism in polycystic ovarian syndrome . Eur J Endocrinol . 2002;147:217
  33. Kolodziejczyk B , Duleba AJ , Spaczynski RZ , Pawelczyk L . Metformin therapy decreases hyperandrogenism and hyperinsulinemia in women with polycystic ovarian syndrome . Fertil Steril . 2000;73:1149
  34. Hung Yu , Ng E , Ming Sun , Wat N , Chung Ho P . Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomiphene-resistant polycystic ovaries: a randomized, double-blinded placebo-controlled trial . Hum Reprod . 2001;16(8):1625
  35. Papunen M , Vanayl  . Endocrine & metabolic effects of metformin versus ethinyl estradiol cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study . J Clin Endocrinol Metab . 2000;85(9):3161–3168
  36. Harbourne L , Fleming R , Lyall H , Sattar N , Norman J . Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome . J Clin Endocrinol Metab . 2003;88(9):4116–4123
  37. Glueck CJ , Wang P , Kobayashi S , et al.   Metformin therapy throughout pregnancy reduces the development of gestational diabetes in women with polycystic ovarian syndrome . Fertil Steril . 2002;77:520
  38. Gilbert C , Valois M , Koren G . Pregnancy outcomes after first trimester exposure to metformin: a meta-analysis . Fertil Steril . 2006;86:658
  39. Jakubowicz DJ , Iuorno MJ , Jakubowicz S , et al.   Effects of metformin on early pregnancy loss in polycystic ovary syndrome . J Clin Endocrinol Metab . 2002;87:524
  40. Glueck CJ , Wang P , Goldenberg N , Sieve-Smith L . Pregnancy outcomes among women with polycystic ovary sydnrome treated with metformin . Hum Reprod . 2002;17:2858
  41. Garmes H , Tambascia M , Santut-Wittman D . Endocrine-metabolic effects of the treatment with pioglitizone in obese patiens with polycystic ovarian syndrome . Gynecol Endocrinol . 2005;21(6):317–323
  42. Dunaif A , Scott D , Finegood D , et al.   The insulin-sensitizing agent roglitazone improves the metabolic and reproductive abnormalities in the polycystic ovary syndrome . J Clin Endocrinol Metab . 1996;81:3299
  43. Ortega-Gonzalez C , Luna S , Hernandez L , et al.   Responses of serum androgens and insulin resistance to metformin and piolglitazone in obese, insulin-resistant women with polycystic ovarian syndrome . J Clin Epidemiol . 2005;90(3):1360–1365
  44. Yilmaz M , Karakoc A , Toruner F , Cakir N , Tiras B , et al.   The effect of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovarian syndrome . Gynecol Endocrinol . 2005;21(3):154–160
  45. Murry R . Polycystic ovarian sydnrome, obesity and insulin resistance: the new female triad . Adv Nurse Practitioners . 2004;23–35
  46. Yildiz B . Oral contraceptive in polycystic ovarian syndrome: risk-benefit assessment . Semin Reprod Med . 2008;26(1):111–120
  47. Legro RS , BArnhart HX , Schlaff WD , et al.   Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome . N Engl J Med . 2007;356:551

 In compliance with national with national ethical guidelines, the author reports no relationships with business or industry that would pose a conflict of interest.

PII: S1555-4155(08)00458-3

doi: 10.1016/j.nurpra.2008.08.005

The Journal for Nurse Practitioners
Volume 4, Issue 9 , Pages 697-704 , October 2008

Article Tools